Reyon Pharmaceutical Co Ltd (102460) — Cash Flow-to-Debt Ratio
Reyon Pharmaceutical Co Ltd (102460) has a Cash Flow-to-Debt Ratio of -0.01x as of September 2025, meaning its operating cash flow of ₩-1.73 Billion could theoretically repay 0% of its total liabilities (₩239.99 Billion) in one year. See financial flexibility index of Reyon Pharmaceutical Co Ltd to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Reyon Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2008–2024)
Historical debt coverage capacity for Reyon Pharmaceutical Co Ltd across 13 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Reyon Pharmaceutical Co Ltd.
Annual Cash Flow-to-Debt Ratio for Reyon Pharmaceutical Co Ltd (2008–2024)
Year-by-year debt coverage analysis for Reyon Pharmaceutical Co Ltd. Check 102460 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.01x | ₩-1.44 Billion | ₩250.05 Billion | ▼ -116.7% |
| 2023 | 0.03x | ₩8.65 Billion | ₩251.15 Billion | ▼ -6.6% |
| 2022 | 0.04x | ₩8.73 Billion | ₩236.93 Billion | ▼ -26.6% |
| 2021 | 0.05x | ₩11.68 Billion | ₩232.74 Billion | ▼ -4.5% |
| 2020 | 0.05x | ₩4.60 Billion | ₩87.52 Billion | ▲ +122.5% |
| 2019 | -0.23x | ₩-12.18 Billion | ₩52.19 Billion | ▼ -258.6% |
| 2018 | 0.15x | ₩11.45 Billion | ₩77.77 Billion | ▼ -37.5% |
| 2017 | 0.24x | ₩16.76 Billion | ₩71.18 Billion | ▼ -24.3% |
| 2016 | 0.31x | ₩9.47 Billion | ₩30.44 Billion | ▼ -61.4% |
| 2012 | 0.81x | ₩24.65 Billion | ₩30.57 Billion | ▲ +51.0% |
| 2011 | 0.53x | ₩15.34 Billion | ₩28.73 Billion | ▲ +36.2% |
| 2009 | 0.39x | ₩8.68 Billion | ₩22.15 Billion | ▲ +48.2% |
| 2008 | 0.26x | ₩5.99 Billion | ₩22.64 Billion | — |